ATRC,BONE,CDXS,MRIC.OB,SRPT Stock Quote

open in screener | publish chart | save to portfolio | create alert

Settings

ATRC [NASD]

AtriCure, Inc.

Healthcare | Medical Instruments & Supplies | USA

statements

Index	-	P/E	-	EPS (ttm)	-1.16	Insider Own	2.50%	Shs Outstand	44.01M	Perf Week	2.33%
Market Cap	1.96B	Forward P/E	-	EPS next Y	-0.83	Insider Trans	-2.16%	Shs Float	43.45M	Perf Month	20.08%
Income	-45.70M	PEG	-	EPS next Q	-0.28	Inst Own	96.50%	Short Float	4.33%	Perf Quarter	3.10%
Sales	210.10M	P/S	9.35	EPS this Y	-43.20%	Inst Trans	1.21%	Short Ratio	5.01	Perf Half Y	-6.60%
Book/sh	9.49	P/B	4.62	EPS next Y	17.80%	ROA	-7.30%	Target Price	54.38	Perf Year	46.48%
Cash/sh	5.20	P/C	8.43	EPS next 5Y	20.00%	ROE	-14.00%	52W Range	23.17 - 51.76	Perf YTD	34.85%
Dividend	-	P/FCF	-	EPS past 5Y	-8.80%	ROI	-10.40%	52W High	-15.30%	Beta	1.06
Dividend %	-	Quick Ratio	5.90	Sales past 5Y	16.50%	Gross Margin	72.20%	52W Low	89.25%	ATR	1.64
Employees	730	Current Ratio	6.60	Sales Q/Q	-3.20%	Oper. Margin	-20.00%	RSI (14)	70.76	Volatility	3.20% 4.71%
Optionable	Yes	Debt/Eq	0.15	EPS Q/Q	54.50%	Profit Margin	-21.70%	Rel Volume	0.49	Prev Close	43.63
Shortable	Yes	LT Debt/Eq	0.15	Earnings	Nov 05 AMC	Payout	-	Avg Volume	375.39K	Price	43.84
Recom	1.40	SMA20	11.72%	SMA50	11.68%	SMA200	7.26%	Volume	184,538	Change	0.48%

Nov-06-20

Reiterated

Needham

Buy

$63 → $53

Apr-07-20

Initiated

Oppenheimer

Outperform

$45

Feb-06-20

Initiated

BTIG Research

Buy

$42

Jan-24-20

Reiterated

Needham

Buy

$39 → $48

Aug-13-19

Downgrade

Northland Capital

Outperform → Market Perform

$30

Apr-12-19

Initiated

JP Morgan

Overweight

$37

Oct-04-18

Reiterated

Needham

Buy

$36 → $39

Aug-02-18

Reiterated

Stifel

Buy

$32 → $34

Aug-02-18

Reiterated

Needham

Buy

$32 → $36

Jun-18-18

Reiterated

Needham

Buy

$26 → $32

Apr-27-18

Reiterated

Needham

Buy

$23 → $26

Jan-16-18

Reiterated

Needham

Buy

$25 → $23

Nov-02-17

Reiterated

Needham

Buy

$26 → $25

Jul-28-17

Reiterated

Needham

Buy

$25 → $26

May-30-17

Resumed

Piper Jaffray

Overweight

Jun-30-16

Resumed

JMP Securities

Mkt Outperform

Oct-28-15

Reiterated

Needham

Buy

$30 → $23

Oct-06-15

Reiterated

Needham

Buy

$32 → $30

Oct-06-15

Reiterated

Canaccord Genuity

Buy

$31 → $28

Aug-04-15

Reiterated

Needham

Buy

$29 → $32

Nov-19-20 11:44AM	Insider Buys AtriCure Stock Benzinga +5.00%
08:00AM	AtriCure to Participate in Upcoming Piper Sandler 32nd Annual Virtual Healthcare Conference Business Wire
Nov-06-20 09:30AM	AtriCure Inc (ATRC) Q3 2020 Earnings Call Transcript Motley Fool
Nov-05-20 06:25PM	AtriCure (ATRC) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:01PM	AtriCure Reports Third Quarter 2020 Financial Results Business Wire
02:30PM	AtriCure, Inc. to Host Earnings Call ACCESSWIRE
Oct-29-20 12:35PM	Analysts Estimate AtriCure (ATRC) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-26-20 08:00AM	AtriCure to Participate in Upcoming Investor Conferences Business Wire
Oct-13-20 08:00AM	AtriCure to Announce Third Quarter 2020 Financial Results Business Wire
Oct-06-20 05:41PM	Do Hedge Funds Love AtriCure Inc. (ATRC)? Insider Monkey
Sep-28-20 06:39AM	What We Learned About AtriCure's (NASDAQ:ATRC) CEO Compensation Simply Wall St.
Sep-01-20 08:00AM	AtriCure to Participate at the Morgan Stanley 18th Annual Global Healthcare Conference Business Wire
Aug-06-20 04:00PM	AtriCure Announces Angie Wirick as Chief Financial Officer Business Wire
Aug-03-20 08:55AM	AtriCure Inc. (ATRC): Were Hedge Funds Right About Buying This Stock? Insider Monkey
Jul-30-20 06:39AM	Analysts Have Made A Financial Statement On AtriCure, Inc.'s (NASDAQ:ATRC) Second-Quarter Report Simply Wall St.
Jul-29-20 08:00AM	AtriCure to Participate at Upcoming Investor Conferences Business Wire -5.13%
05:01AM	AtriCure Inc (ATRC) Q2 2020 Earnings Call Transcript Motley Fool
Jul-28-20 04:22PM	Recap: AtriCure Q2 Earnings Benzinga
04:01PM	AtriCure Reports Second Quarter 2020 Financial Results Business Wire
Jul-21-20 12:31PM	Analysts Estimate AtriCure (ATRC) to Report a Decline in Earnings: What to Look Out for Zacks
Jul-07-20 08:00AM	AtriCure to Announce Second Quarter 2020 Financial Results Business Wire -6.39%
Jun-19-20 12:45PM	Hedge Funds Are Buying AtriCure Inc. (ATRC) Insider Monkey
Jun-17-20 04:53AM	Edited Transcript of ATRC.OQ earnings conference call or presentation 29-Apr-20 8:30pm GMT Thomson Reuters StreetEvents
May-11-20 08:10PM	AtriCure Announces Pricing of Public Offering of Common Stock Business Wire
07:16AM	AtriCure Announces Proposed Public Offering of Common Stock Business Wire
May-08-20 08:47AM	AtriCure Announces Results from CONVERGE IDE Clinical Trial Business Wire +7.70%
Apr-30-20 11:00AM	AtriCure Inc (ATRC) Q1 2020 Earnings Call Transcript Motley Fool
08:30AM	AtriCure Announces Investor Update Webcast on May 8, 2020 in Conjunction with the 41st Annual Heart Rhythm Society (HRS) Virtual Meeting Business Wire
Apr-29-20 05:25PM	AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates Zacks +5.61%
04:01PM	AtriCure Reports First Quarter 2020 Financial Results Business Wire
Apr-27-20 04:02PM	AtriCure to Participate at Upcoming Investor Conferences Business Wire
Apr-22-20 12:31PM	Analysts Estimate AtriCure (ATRC) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-15-20 08:00AM	AtriCure to Announce First Quarter 2020 Financial Results Business Wire
Apr-14-20 06:42AM	Some Analysts Just Cut Their AtriCure, Inc. (NASDAQ:ATRC) Estimates Simply Wall St.
Apr-13-20 08:00AM	AtriCure Announces CONVERGE IDE Trial Results Accepted for Late-Breaking Clinical Trial Sessions at Annual Heart Rhythm Society (HRS) Meeting Business Wire
Apr-09-20 12:26PM	AtriCure C-suite taking pay cuts as revenue dips because of coronavirus American City Business Journals
08:00AM	AtriCure Announces Preliminary Financial Results for First Quarter 2020 and Provides COVID-19 Pandemic Update Business Wire
Apr-06-20 04:14PM	Dayton stocks reap massive gains as broad market skyrockets American City Business Journals +7.52%
Apr-01-20 03:00PM	Dayton stocks dive again after Q1 registers biggest drop since 2008 American City Business Journals
Mar-24-20 05:09PM	These Dayton stocks skyrocketed as market posts best day since 1933 American City Business Journals +9.52%
Mar-23-20 02:29PM	Here's how Dayton stocks fared as Dow falls to lowest level since 2016 American City Business Journals
Mar-12-20 09:21AM	Dayton stocks tumble as Dow falls, ending 11-year bull run American City Business Journals -13.35%
Feb-28-20 02:53PM	Dayton stocks face sharp declines as equity market tumbles American City Business Journals
Feb-25-20 10:37PM	Edited Transcript of ATRC earnings conference call or presentation 18-Feb-20 9:30pm GMT Thomson Reuters StreetEvents
Feb-20-20 05:54AM	US$49.43 - That's What Analysts Think AtriCure, Inc. Is Worth After These Results Simply Wall St.
Feb-18-20 04:01PM	AtriCure Reports Fourth Quarter 2019 and Full Year 2019 Financial Results Business Wire
02:30PM	AtriCure, Inc. to Host Earnings Call ACCESSWIRE
Feb-03-20 08:00AM	AtriCure to Participate at the SVB Leerink 9th Annual Global Healthcare Conference Business Wire
Jan-31-20 07:33AM	Is AtriCure (NASDAQ:ATRC) Using Debt Sensibly? Simply Wall St.
Jan-28-20 11:15AM	Here's how Dayton-area stocks performed in 2019 American City Business Journals
08:00AM	AtriCure to Announce Fourth Quarter and Full Year 2019 Financial Results Business Wire
Jan-10-20 08:14AM	AtriCure Enters Overbought Territory Zacks
Jan-07-20 08:00AM	AtriCure Announces Successful Completion of Patient Enrollment of aMAZE Clinical Trial and FDA Approval of Continued Access Protocol Business Wire
Dec-16-19 08:00AM	AtriCure to Participate at the 38th Annual JP Morgan Healthcare Conference Business Wire
Dec-10-19 11:28AM	Why AtriCure CEO Mike Carrel wants title of heart surgeon for a day American City Business Journals
Dec-09-19 01:12PM	Did Hedge Funds Drop The Ball On AtriCure Inc. (ATRC) ? Insider Monkey
Dec-05-19 06:13AM	Medical device maker south of Dayton gets board refresh American City Business Journals
Dec-04-19 08:00AM	AtriCure Names Two Industry Veterans to Board of Directors Business Wire
Dec-02-19 09:33AM	Is AtriCure, Inc.'s (NASDAQ:ATRC) CEO Paid Enough Relative To Peers? Simply Wall St.
Nov-12-19 08:00AM	AtriCure to Participate at the Piper Jaffray 31st Annual Healthcare Conference Business Wire
Nov-06-19 02:22PM	Edited Transcript of ATRC earnings conference call or presentation 30-Oct-19 8:30pm GMT Thomson Reuters StreetEvents
Oct-30-19 06:15PM	AtriCure (ATRC) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:02PM	AtriCure Reports Third Quarter 2019 Financial Results Business Wire
Oct-27-19 02:02PM	Is AtriCure Inc. (ATRC) A Good Stock To Buy ? Insider Monkey
Oct-23-19 10:33AM	Analysts Estimate AtriCure (ATRC) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-21-19 08:00AM	AtriCure to Participate in Upcoming Investor Conferences Business Wire
Oct-09-19 06:18PM	This Hedge Fund Returns 22% Annually, Here Are Its Latest Picks Insider Monkey
Oct-08-19 11:06AM	Does AtriCure's (NASDAQ:ATRC) Share Price Gain of 64% Match Its Business Performance? Simply Wall St.
08:00AM	AtriCure to Announce Third Quarter 2019 Financial Results Business Wire
Sep-02-19 03:18PM	How AtriCure, Inc.'s (NASDAQ:ATRC) Earnings Growth Stacks Up Against The Industry Simply Wall St.
Aug-28-19 10:50AM	AtriCure Gains Expanded Labeling for Atriclip, Braces LAA Arm Zacks
Aug-27-19 08:00AM	AtriCure Receives Clearance for Expanded Labeling Claims for AtriClip Devices Business Wire
Aug-26-19 08:00AM	AtriCure to Participate at the Morgan Stanley 17th Annual Global Healthcare Conference Business Wire
Aug-14-19 02:26PM	The Funded: 6 Bay Area companies raise $274M at midweek American City Business Journals
Aug-13-19 02:16PM	AtriCure Completes Acquisition of SentreHEART Business Wire -5.09%
Aug-12-19 11:04AM	AtriCure could pay up to $300M to acquire California firm American City Business Journals
05:30AM	AtriCure Enters Into Definitive Agreement to Acquire SentreHEART Business Wire
Jul-31-19 02:39PM	Edited Transcript of ATRC earnings conference call or presentation 30-Jul-19 8:30pm GMT Thomson Reuters StreetEvents
08:24AM	AtriCure Inc (ATRC) Q2 2019 Earnings Call Transcript Motley Fool
Jul-30-19 06:35PM	AtriCure (ATRC) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:02PM	AtriCure Reports Second Quarter 2019 Financial Results Business Wire
02:30PM	AtriCure, Inc. to Host Earnings Call ACCESSWIRE
Jul-26-19 02:09PM	AtriCure (NASDAQ:ATRC) May Be Weighed Down By Its Debt Simply Wall St.
Jul-23-19 10:32AM	Will AtriCure (ATRC) Report Negative Earnings Next Week? What You Should Know Zacks
Jul-17-19 04:00PM	AtriCure to Participate at the Canaccord Genuity 39th Annual Growth Conference Business Wire
Jul-12-19 10:15AM	Atricure Inc (ATRC) President, CEO, & Director Michael H Carrel Sold $800,000 of Shares GuruFocus.com
Jul-10-19 08:00AM	AtriCure to Announce Second Quarter 2019 Financial Results Business Wire
Jul-06-19 07:00AM	Dayton's largest public company executive compensations American City Business Journals
Jun-14-19 09:09AM	Hedge Funds Have Never Been This Bullish On AtriCure Inc. (ATRC) Insider Monkey
May-24-19 01:34PM	Is AtriCure, Inc. (NASDAQ:ATRC) Worth US$29.31 Based On Its Intrinsic Value? Simply Wall St.
May-05-19 03:53PM	These stocks have 'underappreciated' stories, Wall Street analysts say CNBC
May-02-19 02:58PM	Hedge Funds Have Never Been More Bullish On AtriCure Inc. (ATRC) Insider Monkey
May-01-19 07:46PM	Edited Transcript of ATRC earnings conference call or presentation 25-Apr-19 8:30pm GMT Thomson Reuters StreetEvents
Apr-26-19 07:28AM	AtriCure Inc (ATRC) Q1 2019 Earnings Call Transcript Motley Fool
Apr-25-19 05:05PM	AtriCure: 1Q Earnings Snapshot Associated Press
04:01PM	AtriCure Reports First Quarter 2019 Financial Results Business Wire
02:30PM	AtriCure, Inc. to Host Earnings Call ACCESSWIRE
Apr-23-19 08:00AM	AtriCure Announces First Patient Enrollment in the DEEP IDE Trial Restart Business Wire
Apr-18-19 10:33AM	AtriCure (ATRC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Apr-04-19 08:00AM	AtriCure to Announce First Quarter 2019 Financial Results Business Wire

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; EPi-Sense guided coagulation system used for the coagulation of tissue; and COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy. It also provides multifunctional pens that allow surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and linear ablation devices, which enable users to make longer linear lines of ablation. In addition, the company offers cryoICE cryoablation system used to ablate cardiac tissue for the treatment of cardiac arrhythmias; AtriClip system used to occlude the left atrial appendage by mechanically clamping the appendage; and CryoICE CRYO2 cryoablation system to apply cryo-energy to targeted intercostal peripheral nerves in the ribcage and temporarily relieve pain. Further, it provides Lumitip dissector to separate tissues to provide access to key anatomical structures that are targeted for ablation; Fusion Magnetic Retriever System that allows access around anatomical structures; and cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. The company sells its products through independent distributors and direct sales personnel. The company was founded in 2000 and is headquartered in Mason, Ohio.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Drake Scott William	Director	Nov 17	Buy	40.54	12,350	500,669	41,036	Nov 19 07:40 AM
Seith Douglas J	Chief Operating Officer	Oct 09	Sale	40.09	29,161	1,169,064	129,497	Oct 13 08:23 AM
Collar Mark A	Director	Oct 06	Sale	40.00	2,330	93,200	78,558	Oct 08 08:39 AM
Collar Mark A	Director	Oct 01	Sale	40.20	670	26,934	80,888	Oct 05 08:45 AM
GROVES REGINA E	Director	Sep 14	Sale	41.83	6,313	264,073	21,809	Sep 16 04:12 PM
Collar Mark A	Director	Jul 01	Sale	44.60	4,000	178,400	81,558	Jul 06 08:21 AM
Collar Mark A	Director	May 12	Option Exercise	5.15	10,000	51,500	83,106	May 14 08:12 AM
CARREL MICHAEL H	President, CEO, & Director	May 12	Option Exercise	5.91	25,000	147,750	539,147	May 13 04:57 PM
CARREL MICHAEL H	President, CEO, & Director	May 12	Sale	47.00	25,000	1,175,000	514,147	May 13 04:57 PM
CARREL MICHAEL H	President, CEO, & Director	May 11	Option Exercise	5.91	25,000	147,750	539,147	May 13 04:57 PM
CARREL MICHAEL H	President, CEO, & Director	May 11	Sale	46.00	25,000	1,150,000	514,147	May 13 04:57 PM
CARREL MICHAEL H	President, CEO, & Director	May 08	Option Exercise	5.91	25,000	147,750	539,147	May 08 05:02 PM
CARREL MICHAEL H	President, CEO, & Director	May 08	Sale	45.00	25,000	1,125,000	514,147	May 08 05:02 PM
Lanning Mark R	Director	Apr 27	Option Exercise	5.15	10,000	51,500	128,434	Apr 29 08:03 AM
Noznesky Justin J	SVP, Mktg & Business Develop	Apr 17	Sale	40.00	10,000	400,000	51,255	Apr 20 08:01 AM
Collar Mark A	Director	Apr 07	Sale	36.07	4,000	144,280	73,106	Apr 09 08:09 AM
Noznesky Justin J	SVP, Mktg & Business Develop	Apr 07	Sale	35.00	10,000	350,000	61,255	Apr 09 08:05 AM
Wade M. Andrew	CFO	Feb 21	Option Exercise	6.58	45,000	295,950	160,120	Feb 24 08:14 AM
Wade M. Andrew	CFO	Feb 21	Sale	39.45	45,000	1,775,400	145,120	Feb 24 08:14 AM
CARREL MICHAEL H	President, CEO, & Director	Feb 14	Option Exercise	5.91	25,000	147,750	651,490	Feb 18 08:07 AM
CARREL MICHAEL H	President, CEO, & Director	Feb 14	Sale	44.00	25,000	1,100,000	626,490	Feb 18 08:07 AM
CARREL MICHAEL H	President, CEO, & Director	Feb 13	Option Exercise	5.91	25,000	147,750	651,490	Feb 14 08:40 AM
CARREL MICHAEL H	President, CEO, & Director	Feb 13	Sale	43.00	25,000	1,075,000	626,490	Feb 14 08:40 AM
CARREL MICHAEL H	President, CEO, & Director	Feb 11	Option Exercise	5.91	25,000	147,750	651,490	Feb 12 08:08 AM
Seith Douglas J	Chief Operating Officer	Feb 11	Option Exercise	21.04	50,000	1,052,000	201,299	Feb 13 08:07 AM
CARREL MICHAEL H	President, CEO, & Director	Feb 11	Sale	42.00	25,000	1,050,000	626,490	Feb 12 08:08 AM
CARREL MICHAEL H	President, CEO, & Director	Feb 10	Option Exercise	5.91	25,000	147,750	651,490	Feb 12 08:08 AM
CARREL MICHAEL H	President, CEO, & Director	Feb 10	Sale	41.00	25,000	1,025,000	626,490	Feb 12 08:08 AM
CARREL MICHAEL H	President, CEO, & Director	Jan 29	Option Exercise	5.91	25,000	147,750	651,490	Jan 31 07:35 AM
Seith Douglas J	Chief Operating Officer	Jan 29	Option Exercise	6.73	37,000	249,010	169,682	Jan 31 07:32 AM
CARREL MICHAEL H	President, CEO, & Director	Jan 29	Sale	40.00	25,000	1,000,000	626,490	Jan 31 07:35 AM
Seith Douglas J	Chief Operating Officer	Jan 17	Option Exercise	6.73	38,000	255,740	147,772	Jan 21 08:47 AM
Wade M. Andrew	SVP and CFO	Jan 16	Option Exercise	6.27	10,000	62,700	155,120	Jan 17 07:41 AM
Wade M. Andrew	SVP and CFO	Jan 16	Sale	36.00	10,000	360,000	145,120	Jan 17 07:41 AM
Seith Douglas J	Chief Operating Officer	Jan 16	Sale	36.00	25,471	916,956	106,272	Jan 17 07:44 AM
CARREL MICHAEL H	President, CEO, & Director	Jan 15	Option Exercise	5.91	25,000	147,750	651,490	Jan 16 07:22 AM
CARREL MICHAEL H	President, CEO, & Director	Jan 15	Sale	35.00	25,000	875,000	626,490	Jan 16 07:22 AM
Collar Mark A	Director	Jan 15	Sale	35.02	4,000	140,080	77,106	Jan 17 07:38 AM
CARREL MICHAEL H	President, CEO, & Director	Jan 14	Option Exercise	5.91	25,000	147,750	651,490	Jan 16 07:22 AM
Wade M. Andrew	SVP and CFO	Jan 14	Option Exercise	6.27	10,000	62,700	155,120	Jan 16 07:55 AM
Wade M. Andrew	SVP and CFO	Jan 14	Sale	34.00	10,000	340,000	145,120	Jan 16 07:55 AM
Seith Douglas J	Chief Operating Officer	Jan 14	Sale	34.00	36,363	1,236,342	131,743	Jan 16 07:31 AM
CARREL MICHAEL H	President, CEO, & Director	Jan 14	Sale	34.00	25,000	850,000	626,490	Jan 16 07:22 AM
Noznesky Justin J	SVP, Mktg & Business Develop	Jan 02	Option Exercise	18.30	15,000	274,500	106,568	Jan 06 07:34 AM
CARREL MICHAEL H	President, CEO, & Director	Jan 02	Option Exercise	5.91	23,546	139,157	650,036	Jan 06 07:36 AM
CARREL MICHAEL H	President, CEO, & Director	Jan 02	Sale	33.00	23,546	777,018	626,490	Jan 06 07:36 AM
Noznesky Justin J	SVP, Mktg & Business Develop	Jan 02	Sale	32.89	29,134	958,217	77,434	Jan 06 07:34 AM
Wade M. Andrew	SVP and CFO	Dec 26	Option Exercise	11.20	1,000	11,200	145,715	Dec 30 07:49 AM
Seith Douglas J	Chief Operating Officer	Dec 26	Sale	32.00	31,440	1,006,080	168,106	Dec 30 07:46 AM
Wade M. Andrew	SVP and CFO	Dec 26	Sale	32.00	1,000	32,000	144,715	Dec 30 07:49 AM

open in screener | open in yahoo | open in reuters | open in google

publish chart | save to portfolio | create alert

CDXS [NASD]

Codexis, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-0.35	Insider Own	1.10%	Shs Outstand	59.06M	Perf Week	9.42%
Market Cap	1.06B	Forward P/E	-	EPS next Y	-0.41	Insider Trans	-11.44%	Shs Float	57.32M	Perf Month	32.72%
Income	-20.70M	PEG	-	EPS next Q	-0.12	Inst Own	91.70%	Short Float	8.33%	Perf Quarter	30.51%
Sales	66.70M	P/S	15.87	EPS this Y	-1.30%	Inst Trans	0.47%	Short Ratio	15.78	Perf Half Y	45.83%
Book/sh	1.54	P/B	11.69	EPS next Y	10.90%	ROA	-14.30%	Target Price	19.33	Perf Year	14.49%
Cash/sh	1.22	P/C	14.81	EPS next 5Y	15.00%	ROE	-21.20%	52W Range	8.43 - 18.87	Perf YTD	12.63%
Dividend	-	P/FCF	-	EPS past 5Y	15.80%	ROI	-11.90%	52W High	-4.56%	Beta	1.08
Dividend %	-	Quick Ratio	5.00	Sales past 5Y	14.20%	Gross Margin	83.10%	52W Low	113.64%	ATR	0.62
Employees	161	Current Ratio	5.00	Sales Q/Q	-16.00%	Oper. Margin	-31.20%	RSI (14)	80.62	Volatility	4.08% 4.34%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-	Profit Margin	-31.10%	Rel Volume	0.59	Prev Close	17.86
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Nov 05 AMC	Payout	-	Avg Volume	302.50K	Price	18.01
Recom	1.70	SMA20	16.54%	SMA50	28.56%	SMA200	45.79%	Volume	179,631	Change	0.84%

Mar-10-20

Initiated

The Benchmark Company

Buy

Jan-17-19

Upgrade

First Analysis Sec

Neutral → Outperform

$12 → $19

May-16-18

Initiated

Stephens

Overweight

$16

Oct-13-17

Reiterated

H.C. Wainwright

Buy

$8 → $8.50

May-31-17

Initiated

Jefferies

Buy

Jan-26-17

Downgrade

First Analysis Sec

Overweight → Equal-Weight

$5.50

Jan-04-17

Upgrade

Ladenburg Thalmann

Neutral → Buy

Jan-06-16

Initiated

H.C. Wainwright

Buy

Nov-24-20 05:02PM	Codexis and Casdin Capital Launch SynBio Innovation Accelerator GlobeNewswire
Nov-09-20 07:00AM	Codexis to Participate at Three Virtual Investment Conferences in November GlobeNewswire +6.97%
Nov-07-20 08:38AM	Codexis (NASDAQ:CDXS) Shareholders Have Enjoyed A Whopping 305% Share Price Gain Simply Wall St.
Nov-05-20 08:30PM	Codexis (CDXS) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:05PM	Codexis Reports Third Quarter 2020 Financial Results GlobeNewswire
02:45PM	Codexis, Inc. to Host Earnings Call ACCESSWIRE
Oct-29-20 07:00AM	Codexis to Hold Third Quarter 2020 Conference Call on November 5 GlobeNewswire
Sep-08-20 07:00AM	Codexis to Present at Two Virtual Investment Conferences in September GlobeNewswire
Aug-11-20 08:33AM	Codexis Dodges Coronavirus Slowdown in Q2 Motley Fool
Aug-06-20 04:05PM	Codexis Reports Second Quarter 2020 Financial Results GlobeNewswire
07:00AM	Codexis Adds Dr. Jennifer L. Aaker to its Board of Directors GlobeNewswire
Jul-30-20 07:00AM	Codexis to Hold Second Quarter 2020 Conference Call on August 6 GlobeNewswire
Jul-28-20 12:33PM	Earnings Preview: Codexis (CDXS) Q2 Earnings Expected to Decline Zacks
Jun-23-20 07:00AM	Codexis and Molecular Assemblies Partner to Transform the Field of DNA Synthesis GlobeNewswire
Jun-22-20 03:06PM	Hedge Funds Are Selling Codexis, Inc. (CDXS) Insider Monkey
Jun-16-20 04:05PM	Codexis Announces the Election of New Directors at its Annual Meeting of Stockholders GlobeNewswire
Jun-14-20 03:50PM	Edited Transcript of CDXS.OQ earnings conference call or presentation 7-May-20 8:30pm GMT Thomson Reuters StreetEvents
Jun-01-20 04:05PM	Codexis and Alphazyme Partner to Offer Novel Enzymes to Life Science and Diagnostic Markets GlobeNewswire
May-27-20 07:00AM	Codexis to Participate in Two Virtual Investment Conferences GlobeNewswire
May-22-20 07:31PM	Should Codexis Investors Prepare for Slower Growth? Motley Fool
May-11-20 07:00AM	Codexis to Present at the UBS Virtual Healthcare Conference GlobeNewswire
06:51AM	H.C. Wainwright Sticks to Their Buy Rating for Codexis Investing.com
May-09-20 01:30AM	Codexis(CDXS) Q1 2020 Earnings Call Transcript Motley Fool
May-07-20 04:05PM	Codexis Reports First Quarter 2020 Financial Results GlobeNewswire
May-06-20 04:05PM	Codexis Achieves Technology Transfer Milestone with Global Pharmaceutical Leader GlobeNewswire
May-05-20 07:00AM	Codexis Expands and Strengthens its Leadership Team with Two Executive Hires GlobeNewswire +5.83%
Apr-30-20 07:00AM	Codexis to Hold First Quarter 2020 Conference Call on May 7 GlobeNewswire
Apr-27-20 12:31PM	Earnings Preview: Codexis (CDXS) Q1 Earnings Expected to Decline Zacks +6.19%
Apr-07-20 08:37AM	Is Codexis, Inc.'s (NASDAQ:CDXS) CEO Pay Justified? Simply Wall St.
Mar-23-20 07:00AM	Codexis Signs Strategic Collaboration and License Agreement with Takeda to Advance Novel Gene Therapies for Rare Genetic Disorders GlobeNewswire +11.02%
Mar-13-20 01:57PM	Edited Transcript of CDXS earnings conference call or presentation 27-Feb-20 9:30pm GMT Thomson Reuters StreetEvents +8.41%
Mar-02-20 10:15AM	Company News for Mar 2, 2020 Zacks
Mar-01-20 07:19AM	Analysts Have Been Trimming Their Codexis, Inc. Price Target After Its Latest Report Simply Wall St.
Feb-27-20 06:55PM	Codexis (CDXS) Q4 Earnings and Revenues Lag Estimates Zacks
04:05PM	Codexis Reports 2019 Fourth Quarter and Full Year Financial Results GlobeNewswire
Feb-25-20 07:00AM	Codexis to Present at Two Investment Conferences in March GlobeNewswire
Feb-20-20 07:00AM	Codexis to Hold 2019 Fourth Quarter and Full Year Conference Call on February 27 GlobeNewswire
Jan-31-20 07:52AM	Have Insiders Been Buying Codexis, Inc. (NASDAQ:CDXS) Shares This Year? Simply Wall St.
Jan-13-20 04:05PM	Codexis Attends Opening Ceremony for Portons Fermentation Pilot Lab in Chongqing GlobeNewswire
Jan-10-20 07:00AM	Codexis and Nestlé Health Science Sign Development Agreement to Advance Therapeutic Candidate towards Clinical Studies and Extend Strategic Collaboration Agreement GlobeNewswire
Jan-01-20 09:06AM	We're Not Very Worried About Codexis's (NASDAQ:CDXS) Cash Burn Rate Simply Wall St.
Dec-24-19 07:24AM	The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict Benzinga
Dec-23-19 07:00AM	Codexis Announces License Agreement with Roche for Enzyme Used in Next Generation Sequencing GlobeNewswire
Dec-16-19 06:10AM	Hedge Funds Are Dumping Codexis, Inc. (CDXS) Insider Monkey
Dec-05-19 04:05PM	Codexis Announces the Publication with Merck of an Efficient Enzymatic Cascade Process for Synthesis of Investigational Anti-HIV Agent, Islatravir GlobeNewswire
Dec-02-19 12:32PM	Codexis (NASDAQ:CDXS) Shareholders Have Enjoyed A Whopping 567% Share Price Gain Simply Wall St.
Nov-16-19 09:39PM	Edited Transcript of CDXS earnings conference call or presentation 5-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-06-19 09:00AM	Codexis (CDXS) Upgraded to Buy: What Does It Mean for the Stock? Zacks +9.43%
Nov-05-19 07:55PM	Codexis (CDXS) Q3 Earnings and Revenues Beat Estimates Zacks
04:05PM	Codexis Reports Third Quarter 2019 Financial Results GlobeNewswire
07:00AM	Codexis to Participate in Four Investment Conferences in November GlobeNewswire
Oct-29-19 07:00AM	Codexis to Hold Third Quarter 2019 Conference Call on November 5 GlobeNewswire
Oct-27-19 08:13PM	Is Codexis, Inc. (CDXS) A Good Stock To Buy ? Insider Monkey
Oct-26-19 09:13AM	A Look At The Fair Value Of Codexis, Inc. (NASDAQ:CDXS) Simply Wall St.
Oct-15-19 04:05PM	Codexis Protein Engineering Forum Highlights Progress and Future Direction of the Field GlobeNewswire
Sep-26-19 08:00AM	Codexis Spreading the Promise of Engineered Proteins at SynBioBeta Summit Business Wire
07:00AM	Codexis to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Sep-20-19 06:57AM	Is Codexis, Inc.'s (NASDAQ:CDXS) CEO Pay Justified? Simply Wall St.
Aug-29-19 07:11AM	3 Top Stocks Under $20 Motley Fool
Aug-22-19 11:15PM	Codexis Inc (CDXS) President and CEO John J Nicols Bought $133,000 of Shares GuruFocus.com
Aug-09-19 01:32PM	Edited Transcript of CDXS earnings conference call or presentation 6-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-07-19 03:49PM	Codexis Rolls Into Second Half Armed with Cash Motley Fool -16.07%
08:25AM	Codexis(CDXS) Q2 2019 Earnings Call Transcript Motley Fool
Aug-06-19 07:35PM	Codexis (CDXS) Reports Q2 Loss, Lags Revenue Estimates Zacks
04:06PM	Codexis Reports Second Quarter 2019 Financial Results GlobeNewswire
Jul-30-19 07:00AM	Codexis to Hold Second Quarter 2019 Conference Call on August 6 GlobeNewswire
Jun-27-19 03:01PM	3 Top Stocks Under $20 Motley Fool
Jun-20-19 07:00AM	Casdin Capital Invests $50 Million in Codexis to Accelerate Strategic Growth Initiatives GlobeNewswire
Jun-10-19 12:06PM	Is Codexis a Buy? Motley Fool
May-30-19 07:00AM	Codexis to Present at the Jefferies 2019 Global Healthcare Conference GlobeNewswire
May-16-19 09:34AM	Who Has Been Selling Codexis, Inc. (NASDAQ:CDXS) Shares? Simply Wall St.
May-15-19 09:00AM	Codexis Announces CodeEvolver® Technology Transfer and License Agreement with Global Pharmaceutical Leader GlobeNewswire
May-14-19 04:05PM	Codexis to Participate at Three Investment Conferences in May GlobeNewswire
May-10-19 01:51AM	Edited Transcript of CDXS earnings conference call or presentation 6-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-09-19 10:07AM	Codexis Bags Novartis as Software Customer, Stays Course in First Quarter Motley Fool
May-07-19 10:57AM	Hedge Funds Have Never Been This Bullish On Codexis, Inc. (CDXS) Insider Monkey -6.55%
03:23AM	Codexis(CDXS) Q1 2019 Earnings Call Transcript Motley Fool
May-06-19 07:25PM	Codexis (CDXS) Reports Q1 Loss, Tops Revenue Estimates Zacks
06:19PM	Codexis: 1Q Earnings Snapshot Associated Press
04:06PM	Codexis Reports First Quarter 2019 Financial Results GlobeNewswire
Apr-30-19 10:54AM	3 Stocks That Could Help You Send Your Kids to College Motley Fool
07:00AM	Codexis Signs Multi-Year Enzyme Supply and Licensing Agreement with Tate & Lyle for the Manufacture of TASTEVA® M Stevia Sweetener GlobeNewswire
Apr-29-19 07:00AM	Codexis to Hold First Quarter 2019 Conference Call on May 6 GlobeNewswire
Apr-19-19 02:09PM	Investors Who Bought Codexis (NASDAQ:CDXS) Shares Five Years Ago Are Now Up 1053% Simply Wall St.
Apr-05-19 04:05PM	Codexis Senior Vice President of R&D Dr. Jim Lalonde Announces Plan to Resign GlobeNewswire
Mar-22-19 09:41AM	3 Stocks Poised for Huge Growth Over the Next Decade Motley Fool -6.03%
Mar-14-19 11:15AM	Codexis (CDXS) Q4 Earnings Beat Estimates Zacks
Mar-07-19 01:25PM	Codexis, Inc. (NASDAQ:CDXS) Is Expected To Breakeven Simply Wall St.
Mar-05-19 07:00AM	Codexis to Participate in Two Investment Conferences in March GlobeNewswire
Mar-02-19 11:48AM	Codexis Inc (CDXS) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com
Mar-01-19 07:45AM	Analysis: Positioning to Benefit within Synchrony Financial, KKR & Co., Life Storage, Unum Group, Codexis, and Finisar Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
06:57AM	Edited Transcript of CDXS earnings conference call or presentation 26-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
Feb-27-19 10:18AM	Codexis Hits the Mark in 2018, Expects Revenue to Climb 16% in 2019 Motley Fool
Feb-26-19 08:14PM	Codexis Inc (CDXS) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:05PM	Codexis Reports 2018 Fourth Quarter and Full Year Financial Results GlobeNewswire
Feb-25-19 07:00AM	Codexis Names Laurie Heilmann Senior Vice President of Business Development and Marketing GlobeNewswire
Feb-23-19 09:13AM	3 Stocks the World's Best Investors Are Buying Right Now Motley Fool
Feb-19-19 07:00AM	Codexis to Hold 2018 Fourth Quarter and Full Year Conference Call on February 26 GlobeNewswire
Feb-14-19 07:00AM	Codexis Announces Nestlé Health Science Exercises Option for Exclusive Global License to CDX-6114 for the Management of Phenylketonuria GlobeNewswire
Feb-06-19 07:00AM	Codexis Announces Enzyme Supply Agreement with KYORIN Pharmaceutical for Overactive Bladder Drug Sold in Japan GlobeNewswire

Codexis, Inc. discovers, develops, and sells protein catalysts. It offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering protein catalysts that perform chemical transformations. The company's platform is used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. Its platform also enhances the pharmaceuticals companies manufacturing productivity and efficiency or outsourcing the manufacture of the intermediates and active pharmaceutical ingredients. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KELLEY BERNARD J	Director	Oct 21	Sale	14.00	2,500	35,007	211,136	Oct 23 04:04 PM
Dorgan Byron L	Director	Oct 09	Option Exercise	10.63	25,000	265,750	187,790	Oct 13 04:04 PM
Dorgan Byron L	Director	Oct 09	Sale	13.54	25,000	338,528	162,790	Oct 13 04:04 PM
Dorgan Byron L	Director	Oct 08	Option Exercise	10.63	25,000	265,750	187,790	Oct 13 04:04 PM
Dorgan Byron L	Director	Oct 08	Sale	13.49	25,000	337,315	162,790	Oct 13 04:04 PM
WOLF DENNIS P	Director	Sep 24	Sale	11.68	10,000	116,845	61,129	Sep 28 04:03 PM
KELLEY BERNARD J	Director	Jul 21	Sale	12.79	2,500	31,965	213,636	Jul 23 04:16 PM
WOLF DENNIS P	Director	Jun 25	Sale	10.97	10,000	109,694	71,129	Jun 26 04:18 PM
BARUCH THOMAS R	Director	Jun 12	Sale	10.61	4,947	52,464	33,093	Jun 16 04:03 PM
KELLEY BERNARD J	Director	Apr 21	Sale	10.58	2,500	26,450	207,184	Apr 23 04:07 PM
BARUCH THOMAS R	Director	Apr 02	Sale	10.52	7,500	78,866	38,040	Apr 03 04:07 PM
BARUCH THOMAS R	Director	Apr 01	Sale	10.88	7,500	81,576	45,540	Apr 03 04:07 PM
WOLF DENNIS P	Director	Mar 25	Sale	10.38	10,000	103,785	72,177	Mar 27 04:42 PM
Dorgan Byron L	Director	Feb 21	Sale	14.02	16,702	234,192	153,838	Feb 25 06:02 PM
KELLEY BERNARD J	Director	Jan 21	Sale	18.00	2,500	45,000	209,684	Jan 22 05:20 PM
BARUCH THOMAS R	Director	Jan 16	Sale	18.61	10,000	186,090	53,040	Jan 17 04:18 PM
BARUCH THOMAS R	Director	Jan 15	Sale	18.68	10,000	186,816	63,040	Jan 17 04:18 PM
WOLF DENNIS P	Director	Dec 19	Option Exercise	3.62	20,000	72,400	102,177	Dec 20 05:07 PM
WOLF DENNIS P	Director	Dec 19	Sale	16.22	20,000	324,384	82,177	Dec 20 05:07 PM
Dorgan Byron L	Director	Dec 12	Sale	15.64	25,000	390,973	170,540	Dec 13 04:10 PM
BARUCH THOMAS R	Director	Dec 11	Sale	15.59	17,500	272,892	73,040	Dec 12 04:10 PM
BARUCH THOMAS R	Director	Dec 10	Sale	15.61	17,500	273,236	90,540	Dec 12 04:10 PM

open in screener | open in yahoo | open in reuters | open in google

publish chart | save to portfolio | create alert

SRPT [NASD]

Sarepta Therapeutics, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-7.83	Insider Own	4.10%	Shs Outstand	78.50M	Perf Week	3.52%
Market Cap	10.71B	Forward P/E	-	EPS next Y	-4.94	Insider Trans	-4.22%	Shs Float	75.12M	Perf Month	-0.84%
Income	-600.50M	PEG	-	EPS next Q	-1.81	Inst Own	92.60%	Short Float	11.01%	Perf Quarter	-5.64%
Sales	495.10M	P/S	21.63	EPS this Y	-77.80%	Inst Trans	-2.53%	Short Ratio	12.06	Perf Half Y	-7.08%
Book/sh	11.36	P/B	12.25	EPS next Y	24.50%	ROA	-23.00%	Target Price	189.68	Perf Year	25.45%
Cash/sh	23.59	P/C	5.90	EPS next 5Y	-	ROE	-61.60%	52W Range	78.06 - 175.00	Perf YTD	7.83%
Dividend	-	P/FCF	225.96	EPS past 5Y	-23.40%	ROI	-47.10%	52W High	-20.49%	Beta	1.93
Dividend %	-	Quick Ratio	5.60	Sales past 5Y	108.10%	Gross Margin	88.60%	52W Low	78.26%	ATR	5.73
Employees	743	Current Ratio	6.10	Sales Q/Q	45.40%	Oper. Margin	-	RSI (14)	52.69	Volatility	3.26% 5.01%
Optionable	Yes	Debt/Eq	0.79	EPS Q/Q	-47.00%	Profit Margin	-	Rel Volume	0.28	Prev Close	135.72
Shortable	Yes	LT Debt/Eq	0.79	Earnings	Nov 05 AMC	Payout	-	Avg Volume	685.97K	Price	139.15
Recom	1.80	SMA20	1.91%	SMA50	-0.30%	SMA200	1.71%	Volume	194,776	Change	2.53%

Nov-11-20

Initiated

Berenberg

Hold

Oct-28-20

Initiated

UBS

Buy

$212

Aug-25-20

Initiated

Raymond James

Outperform

$200

Aug-20-20

Downgrade

Credit Suisse

Outperform → Neutral

$185 → $167

Mar-31-20

Initiated

Mizuho

Buy

$183

Nov-01-19

Initiated

Guggenheim

Buy

$183

Aug-21-19

Reiterated

Needham

Buy

$196 → $170

Jul-09-19

Reiterated

Morgan Stanley

Overweight

$165 → $220

Jul-01-19

Reiterated

RBC Capital Mkts

Outperform

$188 → $220

Apr-12-19

Initiated

Evercore ISI

Outperform

Mar-11-19

Reiterated

Credit Suisse

Outperform

$189 → $207

Oct-12-18

Initiated

Bernstein

Outperform

Oct-01-18

Initiated

Cantor Fitzgerald

Overweight

$217

Sep-26-18

Reiterated

RBC Capital Mkts

Outperform

$187 → $200

Sep-14-18

Resumed

BofA/Merrill

Buy

$199

Sep-06-18

Initiated

Credit Suisse

Outperform

$178

Aug-01-18

Upgrade

Morgan Stanley

Equal-Weight → Overweight

Jun-21-18

Reiterated

Robert W. Baird

Outperform

$120 → $202

Jun-20-18

Reiterated

Needham

Buy

$109 → $204

Jun-19-18

Reiterated

H.C. Wainwright

Buy

$96 → $267

Nov-25-20 08:30AM	Sarepta Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Virtual Conference GlobeNewswire
Nov-20-20 08:30AM	Sarepta Therapeutics Named One of The Boston Globes Top Places to Work 2020 GlobeNewswire
Nov-09-20 09:30AM	Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Just Released Its Third-Quarter Earnings: Here's What Analysts Think Simply Wall St.
Nov-06-20 02:27PM	Sarepta Therapeutics Inc (SRPT): Are Hedge Funds Right About This Stock? Insider Monkey -13.43%
12:01PM	Sarepta Therapeutics (SRPT) Q3 2020 Earnings Call Transcript Motley Fool
10:51AM	Sarepta (SRPT) Q3 Loss Widens Y/Y, Revenues Beat Estimates Zacks
Nov-05-20 04:59PM	This Biotech's Gene Therapy Sales Grew 23% But That Wasn't Enough Investor's Business Daily
04:05PM	Sarepta Therapeutics Announces Third Quarter 2020 Financial Results and Recent Corporate Developments GlobeNewswire
04:02PM	Sarepta Therapeutics to Commence Dosing of the Next Study with Commercial Process Material for the SRP-9001 Gene Therapy Program for the Treatment of Duchenne Muscular Dystrophy GlobeNewswire
02:45PM	Sarepta Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Nov-02-20 04:30PM	Sarepta Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference GlobeNewswire
Oct-30-20 07:16PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Oct-29-20 02:25PM	Sarepta Therapeutics Clears Key Benchmark, Hitting 80-Plus RS Rating Investor's Business Daily
12:35PM	Analysts Estimate Sarepta Therapeutics (SRPT) to Report a Decline in Earnings: What to Look Out for Zacks
08:36AM	Sarepta Therapeutics to Announce Third Quarter 2020 Financial Results and Recent Corporate Developments on November 5, 2020 GlobeNewswire
Oct-23-20 12:56PM	Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load? Simply Wall St.
Oct-22-20 07:30AM	Gene Therapy Company AavantiBio Launches with $107 Million Series A Financing from Perceptive Advisors, Bain Capital Life Sciences, RA Capital Management and Sarepta Therapeutics GlobeNewswire
Oct-01-20 04:43PM	Pfizer Gets Fast-Track Status For Muscular Dystrophy Therapy Investor's Business Daily
02:56PM	Why Solid Biosciences Stock Has Doubled Today Barrons.com
Sep-30-20 06:15PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Sep-28-20 05:06PM	Sareptas First Gene-Therapy Test Patients Look Good, Two Years Out Barrons.com
08:55AM	Sarepta Therapeutics Reports Sustained Functional Improvement Two Years After Treatment with SRP-9001, its Investigational Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy GlobeNewswire
08:55AM	Sarepta Therapeutics Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Functional Improvements 18-months After Administration GlobeNewswire
Sep-16-20 10:29AM	How Pfizer Plans to Lead the Industry in Gene Therapies Barrons.com
Sep-15-20 08:30AM	Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program GlobeNewswire
Sep-14-20 08:30AM	Long-term functional data from Sarepta Therapeutics Most Advanced Gene Therapy Programs to be Presented at Upcoming Annual Congress of the World Muscle Society GlobeNewswire +5.98%
Sep-10-20 04:32PM	Sarepta Therapeutics Stock Falls On Delay In Quest For Muscular Dystrophy Treatment Investor's Business Daily
10:19AM	FDA Delays Start of Sareptas Gene Therapy Trial. That Doesnt Faze the Stocks Bulls. Barrons.com
07:38AM	Sarepta shares fall on potential regulatory delay for experimental Duchenne drug MarketWatch
07:20AM	The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Sarepta Flags Potential Delay In Gene Therapy Trial Benzinga
Sep-09-20 05:19PM	Sarepta Therapeutics Provides Program Update for SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy GlobeNewswire
Sep-08-20 11:58PM	Hedge Funds Are Crazy About Sarepta Therapeutics Inc (SRPT) Insider Monkey
03:40PM	If You Had Bought Sarepta Therapeutics (NASDAQ:SRPT) Stock Five Years Ago, You Could Pocket A 248% Gain Today Simply Wall St.
Sep-04-20 11:31AM	Why Is Sarepta Therapeutics (SRPT) Down 11.5% Since Last Earnings Report? Zacks
Sep-03-20 04:30PM	Sarepta Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Aug-31-20 06:30PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Aug-26-20 10:44PM	5 Biotech Stocks That Could Be Worth a Look Barrons.com
11:36AM	Sarepta's Casimersen NDA Gets Priority Review From FDA Zacks
Aug-25-20 04:45PM	Sarepta Therapeutics Gets Fast-Track FDA Review For Muscular Dystrophy Drug Investor's Business Daily
04:45PM	Sarepta Therapeutics Stock Is Now a Top Idea at J.P. Morgan Barrons.com
08:45AM	Sarepta Therapeutics Announces FDA Acceptance of Casimersen (SRP-4045) New Drug Application for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 45 GlobeNewswire
Aug-11-20 10:19AM	Goldman Sachs: These 3 Stocks Are Poised to Soar by at Least 30% TipRanks
08:30AM	Sarepta Therapeutics and University of Florida Announce Collaboration to Accelerate the Discovery and Development of Therapies for Rare Genetic Diseases GlobeNewswire
Aug-06-20 10:54AM	Sarepta (SRPT) Q2 Loss Widens Y/Y, Revenues Beat Estimates Zacks
Aug-05-20 06:05PM	Sarepta Therapeutics (SRPT) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:05PM	Sarepta Therapeutics Announces Second Quarter 2020 Financial Results and Recent Corporate Developments GlobeNewswire
Jul-31-20 06:15PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jul-29-20 12:33PM	Will Sarepta Therapeutics (SRPT) Report Negative Q2 Earnings? What You Should Know Zacks
08:30AM	Sarepta Therapeutics to Announce Second Quarter 2020 Financial Results and Recent Corporate Developments on August 5, 2020 GlobeNewswire
Jul-24-20 01:59PM	Does Sarepta Therapeutics' (NASDAQ:SRPT) CEO Salary Compare Well With The Performance Of The Company? Simply Wall St.
08:30AM	Sarepta Therapeutics Receives Fast Track Designation for SRP-9001 Micro-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular Dystrophy GlobeNewswire
Jul-15-20 08:30AM	Sarepta Therapeutics Launches Rare Lessons Program to Promote Greater Diversity and Inclusion in the Classroom and Support Awareness of Rare Diseases GlobeNewswire
Jul-10-20 08:47PM	Did Hedge Funds Make The Right Call On Sarepta Therapeutics Inc (SRPT) ? Insider Monkey
Jul-02-20 08:21AM	The Daily Biotech Pulse: Novartis Settles Lawsuit For $678M, Sarepta In-Licenses Gene Therapy Pre-Treatment, Unity Biotech Outlines Second-Half Catalysts Benzinga
07:00AM	Sarepta Therapeutics Signs Agreement with Hansa Biopharma for Imlifidase GlobeNewswire
Jun-30-20 06:15PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
08:30AM	Sarepta Therapeutics Announces Retirement of Sandy Mahatme, Chief Financial Officer and Chief Business Officer GlobeNewswire
Jun-29-20 10:06AM	Sarepta Completes Rolling NDA Submission for New DMD Therapy Zacks
Jun-26-20 08:30AM	Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Casimersen (SRP-4045) for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 45 GlobeNewswire
Jun-23-20 04:05PM	Sarepta Addressing Gene Therapy Issue With Two Acquisitions GuruFocus.com
10:27AM	Sarepta Inks Agreement With Codiak to Develop Gene Therapies Zacks
05:43AM	Sarepta, Codiak BioSciences Team Up For Neuromuscular Disease Targeting SmarterAnalyst
Jun-22-20 08:00AM	Sarepta Therapeutics and Codiak BioSciences Collaborate to Research and Develop Exosome-Based Therapeutics for Rare Diseases GlobeNewswire
Jun-18-20 08:30AM	Sarepta Therapeutics and Selecta Biosciences Enter Into Research License and Option Agreement for Selectas ImmTOR Immune Tolerance Platform in Neuromuscular Diseases GlobeNewswire
Jun-16-20 12:00PM	Sarepta Therapeutics (SRPT) Upgraded to Buy: What Does It Mean for the Stock? Zacks
11:30AM	Is Sarepta Therapeutics (SRPT) Stock Outpacing Its Medical Peers This Year? Zacks
Jun-15-20 04:02PM	Sarepta's Gene Therapy for Duchenne Muscular Dystrophy Clears a Major Safety Hurdle Motley Fool
11:00AM	Sarepta Therapeutics Announces Positive Safety and Efficacy Data from the SRP-9001 Micro-Dystrophin Gene Therapy Trial Published in JAMA Neurology GlobeNewswire
Jun-09-20 10:34AM	Sarepta's Gene Therapy Promising in Muscular Dystrophy Study Zacks
08:59AM	Sarepta Therapeutics' Shares March Higher, Can It Continue? Zacks
Jun-08-20 04:15PM	Sarepta Beats Its Own Gene Therapy Expectations And Shares Surge Investor's Business Daily +7.90%
09:47AM	Sarepta Gene Therapy Win Helps to Validate Broader Platform Bloomberg
08:55AM	Sarepta Therapeutics Announces Positive Expression and Functional Data From the SRP-9003 Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E GlobeNewswire
Jun-05-20 04:05PM	Sarepta Therapeutics to Share Clinical Update from SRP-9003 Gene Therapy Trial to Treat Limb-girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy GlobeNewswire
11:31AM	Why Is Sarepta Therapeutics (SRPT) Up 17.3% Since Last Earnings Report? Zacks
Jun-02-20 08:57PM	Is Sarepta Therapeutics Inc (SRPT) Going to Burn These Hedge Funds? Insider Monkey
05:00PM	Sarepta Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
May-29-20 06:28PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
01:50AM	Edited Transcript of SRPT earnings conference call or presentation 6-May-20 8:30pm GMT Thomson Reuters StreetEvents
May-28-20 11:30AM	Is Sarepta Therapeutics (SRPT) Outperforming Other Medical Stocks This Year? Zacks
May-18-20 11:38AM	Sarepta Surges on Rival Pfizer's DMD Gene Therapy Study Data Zacks
10:49AM	Pfizer Reports Efficacy & Safety Data on DMD Gene Therapy Zacks
May-15-20 04:15PM	Why Sarepta Has A Leg Up On Pfizer With A Rival Gene Therapy: Analysts Investor's Business Daily +11.18%
03:37PM	Pfizer Posts Positive Data from Duchenne Muscular Dystrophy Candidate, but Still Trails Rival Sarepta Therapeutics Motley Fool
10:03AM	Sarepta Gains After Pfizer DMD Gene Therapy Data Fall Short Bloomberg
May-14-20 10:53AM	When Will Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Turn A Profit? Simply Wall St.
May-13-20 02:56PM	Pros' Picks: The 15 Best Nasdaq Stocks You Can Buy Kiplinger
May-12-20 04:30PM	Sarepta Therapeutics to Present at the 2020 RBC Capital Markets Virtual Global Healthcare Conference GlobeNewswire
07:52AM	Sarepta Investors Buckle Up for Pfizers DMD Gene Therapy Update Bloomberg
May-11-20 07:00AM	Sarepta Therapeutics and Dyno Therapeutics Announce Agreement to Develop Next-Generation Gene Therapy Vectors for Muscle Diseases GlobeNewswire +6.12%
May-07-20 11:41AM	Sarepta (SRPT) Q1 Loss Widens Y/Y, Revenues Beat Estimates Zacks
07:31AM	Sarepta Therapeutics (SRPT) Q1 2020 Earnings Call Transcript Motley Fool
07:19AM	Sarepta Reports Earnings Miss; But Key SRP-9001 Data Still On Track SmarterAnalyst
May-06-20 06:15PM	Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates Zacks
04:05PM	Sarepta Therapeutics Announces First Quarter 2020 Financial Results and Recent Corporate Developments GlobeNewswire
Apr-30-20 06:52PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Apr-29-20 08:30AM	Sarepta Therapeutics to Announce First Quarter 2020 Financial Results and Recent Corporate Developments on May 6, 2020 GlobeNewswire
06:15AM	Sarepta Therapeutics Revives Anti-Viral Program for Covid-19 Barrons.com
Apr-28-20 08:30AM	Sarepta Therapeutics Announces Research Agreement with U.S. Department of Defense to Evaluate Multiple Constructs From its Proprietary RNA Platform as Treatments for COVID-19 GlobeNewswire
Apr-15-20 08:34AM	The Zacks Analyst Blog Highlights: Meritage Homes, Sarepta Therapeutics, The Clorox Company, The Hain Celestial Group and Entergy Zacks

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities approaches for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. It also developing Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; SRP-9003, a limb-girdle muscular dystrophies gene therapy program; and LYS-SAF 302 to treat mucopolysaccharidosis type IIIA. The company has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; StrideBio; the United States Army Medical Research Institute of Infectious Diseases; the Department of Defense's lead laboratory; the Dyno Therapeutics, Inc; and Personalis, Inc. It also has a research and option agreement with Codiak BioSciences, Inc. to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing, and RNA technologies for neuromuscular diseases. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wigzell Hans Lennart Rudolf	Director	Aug 10	Option Exercise	34.92	10,000	349,200	23,792	Aug 11 08:00 PM
Wigzell Hans Lennart Rudolf	Director	Aug 10	Sale	159.00	10,000	1,590,044	13,792	Aug 11 08:00 PM
Barry Richard	Director	Aug 07	Sale	158.50	30,000	4,754,972	3,129,140	Aug 07 08:00 PM
Bratica Joseph	Principal Financial Officer	Aug 03	Option Exercise	29.60	1,125	33,300	8,957	Aug 05 08:00 PM
Bratica Joseph	Principal Financial Officer	Aug 03	Sale	155.00	1,125	174,375	7,832	Aug 05 08:00 PM
Mahatme Sandesh	EVP, CFO & CBO	Jul 08	Option Exercise	19.69	3,806	74,941	20,260	Jul 09 08:00 PM
Howton David T	EVP, General Counsel	Jun 22	Option Exercise	25.76	105,122	2,708,440	136,993	Jun 22 09:17 PM
Howton David T	EVP, General Counsel	Jun 22	Sale	170.88	105,122	17,962,831	31,871	Jun 22 09:17 PM
Wigzell Hans Lennart Rudolf	Director	May 20	Option Exercise	10.08	5,000	50,400	18,792	May 22 08:00 PM
Wigzell Hans Lennart Rudolf	Director	May 20	Sale	150.64	5,000	753,210	13,792	May 22 08:00 PM
Barry Richard	Director	May 15	Sale	141.26	30,000	4,237,946	3,159,140	May 15 09:02 PM
Wigzell Hans Lennart Rudolf	Director	Mar 04	Option Exercise	8.46	5,000	42,300	18,792	Mar 06 08:01 PM
Wigzell Hans Lennart Rudolf	Director	Mar 04	Sale	116.89	5,000	584,450	13,792	Mar 06 08:01 PM
Mahatme Sandesh	EVP, CFO & CBO	Dec 13	Option Exercise	28.88	125,000	3,610,443	155,179	Dec 17 08:00 PM
Howton David T	EVP, General Counsel	Dec 13	Option Exercise	21.48	78,000	1,675,439	103,171	Dec 17 08:01 PM
Cumbo Alexander	EVP, Chief Commercial Officer	Dec 13	Option Exercise	23.70	32,706	775,232	43,867	Dec 17 08:02 PM
Cumbo Alexander	EVP, Chief Commercial Officer	Dec 13	Sale	125.50	42,000	5,271,000	1,867	Dec 17 08:02 PM
Howton David T	EVP, General Counsel	Dec 13	Sale	125.50	78,000	9,789,000	25,171	Dec 17 08:01 PM
Mahatme Sandesh	EVP, CFO & CBO	Dec 13	Sale	125.50	125,000	15,687,500	30,179	Dec 17 08:00 PM

open in screener | open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience